|
Effect of expression of ICOS in cutaneous T-cell lymphoma and its targeting on killing of malignant cells. |
|
|
Travel, Accommodations, Expenses - Recordati |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck KGaA; MSD Oncology; Novartis; Pierre Fabre; Roche/Genentech; Sun Pharma |
Speakers' Bureau - Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre |
|
|
|
Consulting or Advisory Role - Takeda |
Research Funding - Innate Pharma (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|